AstraZeneca's COVID-19 Vaccine Provides One-Year Immunity

The government continues to pursue the provision of a Covid-19 vaccine to offset the very sharp increase in positive cases. There were several issues regarding vaccines, such as the severe side effects of the Covid-19 vaccine made by AstraZeneca. People were afraid to get vaccinated.

A sub-analysis of a recent study of the AstraZeneca vaccine conducted by Oxford showed it could provide immunity for at least a year after a single dose. It is said that antibody levels remained higher than before, for one year after the first dose was injected.

Moreover, through the press release received Guesehat On June 30, it was stated that if the interval of administering the AstraZeneca vaccine was extended to 45 weeks (the distance between the first and second injections) it would result in a stronger immune response. This research has been published by the University of Oxford in The Lancet.

Also read: POGI Recommendations Regarding Covid-19 Vaccines for Pregnant Women Ibu

An extended interval between the first and second doses of AstraZeneca's COVID-19 vaccine to 45 weeks resulted in an up to 18-fold increase in antibody response, measured 28 days after the second dose.

With a 45-week dosing interval between the first and second doses, antibody titers were four times higher than at 12-week intervals. This shows that a longer dosing interval does not reduce the effectiveness of the vaccine, but instead can provide stronger immunity.

In addition, the third dose of AstraZeneca's COVID-19 vaccine administered at least 6 months after the second dose, increased antibody levels sixfold and maintained T cell response. The third dose also resulted in higher neutralizing activity against the Alpha variant (B.1.1.1.7, 'Kent'), Beta (B.1.351, 'South Africa') and Delta (B.1.617.2, 'India').

Both the extended second dose and the third dose of AstraZeneca's COVID-19 vaccine were less reactogenic than the first dose.

Profesor Sir Andrew J Pollard, Chief Investigator & Director The Oxford Vaccine Group at the University of Oxford, said: “This is good news for countries with limited vaccine supplies, who may be concerned about delays in administering a second dose of vaccine in their country. There was a very good response to the second dose, even after a 10 month delay from the first dose.”

Sir Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, said: “It was important for us to demonstrate that our vaccine produces a strong and long-lasting immune response, to increase confidence regarding long-term protection. We look forward to continuing to partner with the University of Oxford and recommend bodies around the world to further evaluate the impact of these data."

The analysis involved volunteers aged 18 to 55 years who were enrolled in the COV001 and COV002 trials and had received one or two doses of AstraZeneca's COVID-19 vaccine.

Read also: No Need to Choose Covid-19 Vaccine! Experts say, everything is safe

Getting to Know AstraZeneca's COVID-19 Vaccine

As Geng Sehat already knows, the Indonesian government provides several brands of COVID-19 vaccines for the national vaccination program. Starting from Sinovac, AstraZeneca, and will come Pfizer, Sinopharm, and several other vaccines.

AstraZeneca's COVID-19 vaccine co-invented by Oxford University and company spin-out-him, Vaccitech. The vaccine uses a non-replicating chimpanzee virus vector based on an attenuated version of the common cold virus (adenovirus) that causes infection in chimpanzees and contains genetic material from the SARS-CoV-2 viral spike protein.

After vaccination, surface proteins are produced spike which will prepare the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The AstraZeneca vaccine has obtained conditional marketing authorization or emergency use in more than 80 countries on six continents, as a two-dose regimen given four to 12 weeks apart for adults 18 years of age and older. More than 600 million doses of AstraZeneca's COVID-19 Vaccine have been supplied to 170 countries worldwide, including more than 100 countries through the COVAX Facility.

Also read: No Need to Worry, Your Little One Can Stay Immunized During a Pandemic

[embed]https://www.youtube.com/watch?v=VUnHrFXM3KU[/embed]

.

Source link